Showing 8 posts of 8 posts found.

NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine

December 11, 2020
Medical Communications, Sales and Marketing Aimovig, NICE, Novartis, migraine

NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic …


Aimovig reduces frequency of episodic migraines, five-year data reveals

October 6, 2020
Manufacturing and Production, Research and Development Aimovig

Amgen and Novartis have revealed new five-year Phase 2 data during the Migraine Trust Virtual Symposium for their calcitonin gene-related …

NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland

September 26, 2019
Sales and Marketing Aimovig, NICE, Novartis, UK, migraine, pharma

NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales …


4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine

September 9, 2019
Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma

Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …

NICE rejects Novartis’ Aimovig migraine injection for NHS use

January 10, 2019
Sales and Marketing Aimovig, NICE, Novartis, migraine, pharma

It’s disappointing news for Novartis as NICE revealed that it had decided not to recommend Aimovig (erenumab) for routine NHS …


Novartis migraine prevention drug scores EU approval

July 31, 2018
Manufacturing and Production, Sales and Marketing Aimovig, Europe, Novartis, migraine, pharma

Novartis is celebrating the news that its calcitonin gene-related peptide receptor (CGRP-R) pathway therapy Aimovig (erenumab) has been approved by …


Amgen/Novartis migraine med gets CHMP nod

June 4, 2018
Sales and Marketing Aimovig, Amgen, Novartis, biotech, drugs, pharma, pharmaceutical

Amgen and Novartis have announced that their newly FDA-approved treatment for migraines has received a recommendation from the CHMP, generally …


Amgen and Novartis’ Aimovig shines in migraine at Phase 3

April 18, 2018
Research and Development Aimovig, Amgen, Novartis, migraine, pharma

Amgen has lifted the curtain on complete Phase 3 data for its calcitonin gene-related peptide receptor (CGRP) inhibitor Aimovig (erenumab) in …

Latest content